Leadership

Michael S. Anderson was appointed Chief Executive Officer of Flamel Technologies in March 2012. Previously, Anderson was the President and Chief Executive Officer of Éclat Pharmaceuticals, a specialty pharma company located in St. Louis, Missouri. Éclat, which began operation in November 2010, was acquired by Flamel in March of this year. Prior to Eclat, Anderson was at KV Pharmaceutical Company, where he served as President and CEO of its generic business, ETHEX Corporation, and was also the President and CEO of Ther-Rx Corporation, a leader in women’s healthcare. He also was with Schein Pharmaceutical and started his career with A.H. Robins Company. He will be relocating to Lyon, France and Éclat will continue to be operated out of St. Louis.

Dr. Rafael Jorda has been Executive Vice President and Chief Operating Officer of Flamel Technologies SA since 2005. He joined the Company in early 1991. Previously Mr. Jorda worked 14 years as a research and development scientist on controlled-released and biopolymers at Rhone-Poulenc. He is specialized in chemical engineering and in the structure-property relationships of materials. Mr Jorda is a graduate of “Ecole Nationale Supérieure de Chimie de Lyon” (France).

Dr. Stetsko has over 30 years of experience in the pharmaceutical business, with roles of increasing responsibility at Sandoz, Sterling Winthrop, Ligand Pharmaceutical, and Amylin, where he was Vice President of Operations and Global Leader for the Amylin-Lilly Exenatide Alliance.  More recently, he was Chief Scientific Officer for Eagle Pharmaceuticals and a Principal at Tahoe Consulting.  Dr. Stetsko earned a B.S. degree in Pharmacy from the University of Rhode Island and a Ph.D. in Industrial and Physical Pharmacy from Purdue University.

Mrs. Sian Crouzet has been Principal Financial Officer of Flamel Technologies SA since March 2008. She previously worked as Financial Controller France for McCormick & Company Inc. Mrs. Crouzet also worked five years as an external auditor with Ernst and Young (France and UK). She is a UK Chartered Accountant and a graduate of Bradford University (UK).

Mr. Yves Bourboulou is Director of Manufacturing Facility. He worked previously as Plant Manager at Pharmacia and Fresenius Kabi. Mr. Bourboulou previously held various senior positions including Quality Assurance Director and Chief Pharmacist Officer (CPO) in the Pharmaceutical Industry. He has more than 20 years experience in pharmaceutical production, quality and development.

former Chief Executive Officer, Chief Financial Officer and General Counsel of Flamel Technologies, Vice President of Biovail Corporation, Associate Director of Resolutions of the Federal Deposit Insurance Corporation (“FDIC”) of the USA, investment banker at Credit Suisse First Boston, and attorney with Gibson, Dunn Crutcher LLP and Shearman Sterling LLP; member of the Board of Directors of E-Trade Financial Corporation

Chief Executive Officer of Flamel Technologies

Permanent Secretary of the French Academy of Sciences and former Chairwoman of the French National Center for Scientific Research, CNRS

Chairman and CEO of Sotheby’s France

former Senior Vice President: Head of Global Development for AstraZeneca, PLC, Director of ProStrakan Group PLC and Fildes Partners Ltd, and a Fellow of the Royal Society of Medicine and the Royal Society of Chemistry

former United States Ambassador to France

former Group Managing Director of WALLY and former Chief Operating Officer of GrandVision SA, Director of Ingénico, Famar, Conbipel and Deputy Chairman of the Supervisory Board Groupe Loret